Roivant Sciences (NASDAQ:ROIV) Director Sells $640,775.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 17,750 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $36.10, for a total value of $640,775.00. Following the completion of the transaction, the director directly owned 14,954 shares in the company, valued at approximately $539,839.40. This trade represents a 54.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Stock Down 2.2%

Shares of Roivant Sciences stock opened at $34.75 on Thursday. Roivant Sciences Ltd. has a 12 month low of $15.90 and a 12 month high of $42.50. The business has a fifty day simple moving average of $36.68 and a 200 day simple moving average of $32.76. The stock has a market cap of $25.10 billion, a PE ratio of -65.57 and a beta of 1.10.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The business had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Analysts expect that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ROIV. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Citigroup lifted their price target on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. HC Wainwright boosted their price target on shares of Roivant Sciences from $41.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. TD Cowen upped their price objective on shares of Roivant Sciences from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Finally, Guggenheim raised their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and an average target price of $45.64.

Institutional Trading of Roivant Sciences

Several hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its position in shares of Roivant Sciences by 365.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after acquiring an additional 8,621,567 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Roivant Sciences by 18.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock valued at $295,965,000 after acquiring an additional 1,286,464 shares in the last quarter. Perceptive Advisors LLC lifted its position in Roivant Sciences by 3.8% in the 1st quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company’s stock valued at $229,507,000 after acquiring an additional 300,000 shares in the last quarter. Baker BROS. Advisors LP boosted its stake in Roivant Sciences by 47.4% in the 4th quarter. Baker BROS. Advisors LP now owns 5,555,017 shares of the company’s stock worth $120,544,000 after purchasing an additional 1,787,244 shares during the period. Finally, Bank of America Corp DE boosted its stake in Roivant Sciences by 8.0% in the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after purchasing an additional 235,493 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with serious or underserved diseases. The company operates through a network of subsidiary companies, known as “Vants,” each dedicated to specific therapeutic areas, drug candidates or commercial opportunities.

Roivant’s research and development activities have included treatments for immune-mediated diseases, rare disorders, oncology and conditions affecting the nervous system.